These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 11880793)
1. Construct validity of medicare chemotherapy claims: the case of 5FU. Lamont EB; Lauderdale DS; Schilsky RL; Christakis NA Med Care; 2002 Mar; 40(3):201-11. PubMed ID: 11880793 [TBL] [Abstract][Full Text] [Related]
2. Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment. Cooper GS; Yuan Z; Stange KC; Dennis LK; Amini SB; Rimm AA Med Care; 2000 Apr; 38(4):411-21. PubMed ID: 10752973 [TBL] [Abstract][Full Text] [Related]
3. Limited validity of diagnosis codes in Medicare claims for identifying cancer metastases and inferring stage. Chawla N; Yabroff KR; Mariotto A; McNeel TS; Schrag D; Warren JL Ann Epidemiol; 2014 Sep; 24(9):666-72, 672.e1-2. PubMed ID: 25066409 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of adjuvant fluorouracil in clinical practice: a population-based cohort study of elderly patients with stage III colon cancer. Iwashyna TJ; Lamont EB J Clin Oncol; 2002 Oct; 20(19):3992-8. PubMed ID: 12351596 [TBL] [Abstract][Full Text] [Related]
5. Comparison of Medicare Claims-based Proxy Measures of Poor Function and Associations With Treatment Receipt and Mortality in Older Colon Cancer Patients. Mayer SE; Tan HJ; Peacock Hinton S; Sanoff HK; Stürmer T; Hester LL; Faurot KR; Jonsson Funk M; Lund JL Med Care; 2019 Apr; 57(4):286-294. PubMed ID: 30789540 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of three algorithms to identify incident breast cancer in Medicare claims data. Gold HT; Do HT Health Serv Res; 2007 Oct; 42(5):2056-69. PubMed ID: 17850533 [TBL] [Abstract][Full Text] [Related]
7. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Sundararajan V; Mitra N; Jacobson JS; Grann VR; Heitjan DF; Neugut AI Ann Intern Med; 2002 Mar; 136(5):349-57. PubMed ID: 11874307 [TBL] [Abstract][Full Text] [Related]
8. Identifying specific chemotherapeutic agents in Medicare data: a validation study. Lund JL; Stürmer T; Harlan LC; Sanoff HK; Sandler RS; Brookhart MA; Warren JL Med Care; 2013 May; 51(5):e27-34. PubMed ID: 22080337 [TBL] [Abstract][Full Text] [Related]
9. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Nattinger AB; Laud PW; Bajorunaite R; Sparapani RA; Freeman JL Health Serv Res; 2004 Dec; 39(6 Pt 1):1733-49. PubMed ID: 15533184 [TBL] [Abstract][Full Text] [Related]
10. Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Raab GT; Lin A; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Buono DL; Hur C; Kiran RP; Wright JD; Hershman DL; Neugut AI Clin Colorectal Cancer; 2019 Sep; 18(3):e294-e299. PubMed ID: 31266707 [TBL] [Abstract][Full Text] [Related]
11. Patterns of use of chemotherapy for breast cancer in older women: findings from Medicare claims data. Du X; Goodwin JS J Clin Oncol; 2001 Mar; 19(5):1455-61. PubMed ID: 11230491 [TBL] [Abstract][Full Text] [Related]
12. Sensitivity of administrative claims to identify incident cases of lung cancer: a comparison of 3 health plans. Ramsey SD; Scoggins JF; Blough DK; McDermott CL; Reyes CM J Manag Care Pharm; 2009 Oct; 15(8):659-68. PubMed ID: 19803555 [TBL] [Abstract][Full Text] [Related]
13. Hospital-based health care use correlates with incidence of adverse events among elderly Medicare patients treated in adjuvant chemotherapy trials (Alliance 70802). Lamont EB; Yu M; He Y; Saltz L; Muss H; Zaslavsky AM; J Geriatr Oncol; 2014 Jul; 5(3):230-7. PubMed ID: 24594119 [TBL] [Abstract][Full Text] [Related]
14. Completion of therapy by Medicare patients with stage III colon cancer. Dobie SA; Baldwin LM; Dominitz JA; Matthews B; Billingsley K; Barlow W J Natl Cancer Inst; 2006 May; 98(9):610-9. PubMed ID: 16670386 [TBL] [Abstract][Full Text] [Related]
15. Sensitivity of Medicare claims data for measuring use of standard multiagent chemotherapy regimens. Lamont EB; Lan L Med Care; 2014 Mar; 52(3):e15-20. PubMed ID: 22410411 [TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. Schrag D; Rifas-Shiman S; Saltz L; Bach PB; Begg CB J Clin Oncol; 2002 Oct; 20(19):3999-4005. PubMed ID: 12351597 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Comorbid Medical Conditions in the National Cancer Database and the SEER-Medicare Database. Lin CC; Virgo KS; Robbins AS; Jemal A; Ward EM Ann Surg Oncol; 2016 Dec; 23(13):4139-4148. PubMed ID: 27535406 [TBL] [Abstract][Full Text] [Related]
18. Identifying Cancer-Directed Surgeries in Medicare Claims: A Validation Study Using SEER-Medicare Data. Lavery JA; Lipitz-Snyderman A; Li DG; Bach PB; Panageas KS JCO Clin Cancer Inform; 2019 Feb; 3():1-24. PubMed ID: 30715928 [TBL] [Abstract][Full Text] [Related]
19. Utility of the SEER-Medicare data to identify chemotherapy use. Warren JL; Harlan LC; Fahey A; Virnig BA; Freeman JL; Klabunde CN; Cooper GS; Knopf KB Med Care; 2002 Aug; 40(8 Suppl):IV-55-61. PubMed ID: 12187169 [TBL] [Abstract][Full Text] [Related]
20. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. Lamont EB; Herndon JE; Weeks JC; Henderson IC; Lilenbaum R; Schilsky RL; Christakis NA J Natl Cancer Inst; 2005 Jul; 97(14):1080-3. PubMed ID: 16030306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]